Commonwealth Equity Services LLC Raises Stake in Exelixis, Inc. (NASDAQ:EXEL)

Commonwealth Equity Services LLC lifted its position in Exelixis, Inc. (NASDAQ:EXEL) by 4.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 128,033 shares of the biotechnology company’s stock after purchasing an additional 5,037 shares during the period. Commonwealth Equity Services LLC’s holdings in Exelixis were worth $3,038,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of EXEL. China Universal Asset Management Co. Ltd. grew its holdings in Exelixis by 62.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 58,299 shares of the biotechnology company’s stock valued at $1,383,000 after buying an additional 22,324 shares in the last quarter. Milestone Asset Management LLC purchased a new stake in Exelixis in the 1st quarter worth $641,000. First Trust Direct Indexing L.P. bought a new position in shares of Exelixis during the 1st quarter valued at about $250,000. Hennion & Walsh Asset Management Inc. lifted its position in shares of Exelixis by 10.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 69,641 shares of the biotechnology company’s stock worth $1,653,000 after buying an additional 6,490 shares in the last quarter. Finally, Janiczek Wealth Management LLC raised its holdings in shares of Exelixis by 319.6% during the 1st quarter. Janiczek Wealth Management LLC now owns 5,681 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 4,327 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on EXEL. StockNews.com upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 27th. HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of Exelixis in a research note on Friday, May 3rd. Barclays lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 target price on the stock. in a research note on Thursday, April 11th. Stephens began coverage on Exelixis in a research note on Tuesday, May 14th. They issued an “equal weight” rating and a $23.00 price objective on the stock. Finally, TD Cowen lifted their target price on Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Seven investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $26.13.

Exelixis Trading Up 0.1 %

NASDAQ EXEL traded up $0.02 on Friday, reaching $21.98. 152,111 shares of the company were exchanged, compared to its average volume of 2,130,382. The business’s fifty day moving average price is $21.76 and its 200 day moving average price is $22.31. The stock has a market capitalization of $6.66 billion, a P/E ratio of 34.31, a price-to-earnings-growth ratio of 0.54 and a beta of 0.54. Exelixis, Inc. has a fifty-two week low of $18.64 and a fifty-two week high of $24.34.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The company had revenue of $425.23 million for the quarter, compared to analysts’ expectations of $461.04 million. During the same quarter last year, the company earned $0.12 EPS. Exelixis’s revenue for the quarter was up 4.0% compared to the same quarter last year. Equities research analysts forecast that Exelixis, Inc. will post 1.15 earnings per share for the current year.

Insider Buying and Selling

In other Exelixis news, Director Jack L. Wyszomierski sold 8,287 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total transaction of $182,314.00. Following the completion of the sale, the director now directly owns 349,499 shares of the company’s stock, valued at approximately $7,688,978. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Jack L. Wyszomierski sold 8,287 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $22.00, for a total value of $182,314.00. Following the completion of the transaction, the director now directly owns 349,499 shares of the company’s stock, valued at approximately $7,688,978. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Edward Johnson acquired 225,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was purchased at an average cost of $20.76 per share, with a total value of $4,671,000.00. Following the completion of the purchase, the director now directly owns 1,525,730 shares in the company, valued at $31,674,154.80. The disclosure for this purchase can be found here. Insiders have sold 30,896 shares of company stock worth $660,677 in the last quarter. 2.85% of the stock is owned by insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.